PainReform (PRFX) Stock Price, News & Analysis

Company Overview

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Key Stats

• Today's Range: $1.39 to $1.75
• 50-Day Range: $1.34 to $3.00
• 52-Week Range: $1.28 to $17.95
• Volume: 448,655 shs
• Average Volume: 6.77 million shs
• Market Capitalization: $1.44 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

PainReform Stock Analysis - MarketRank™

PainReform scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

PainReform has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

PainReform has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of PainReform is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PainReform is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PainReform has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

54.92% of the float of PainReform has been sold short.

Short Interest Ratio / Days to Cover

PainReform has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PainReform has recently increased by 324.88%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PainReform does not currently pay a dividend.

Dividend Growth

PainReform does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for PainReform this week, compared to 1 article on an average week.

Search Interest

7 people have searched for PRFX on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added PainReform to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PainReform insiders have not sold or bought any company stock.

Percentage Held by Insiders

34.40% of the stock of PainReform is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

37.28% of the stock of PainReform is held by institutions.

Company Calendar

• Last Earnings: 3/26/2026
• Today: 6/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRFX
• CIK: 1801834
• Web: www.painreform.com
• Phone: 972-3717-7051
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.78
• Quick Ratio: 1.78

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 71.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $23.07 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 870,000
• Free Float: 570,000
• Market Cap: $1.44 million
• Optionable: Not Optionable
• Beta: 0.98